Grail Inc
grail.comWhat Do They Do?
Sells Galleri, a blood test that screens for many cancers, to patients through healthcare systems, employers and other health organizations.
10-K for FY2025, filed Mar 12, 2026We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We…View ↗
We designed Galleri to detect cancer early, when it is more amenable to curative treatment. Galleri works by detecting DNA fragments shed…View ↗
The Company recognizes screening revenue from the sale of cancer screening testing services for patients. Patients obtain tests via…View ↗
How Do They Make Money?
Patients and healthcare organizations pay for screening tests; invoices are generally due within 30 days, and GRAIL earns the sale when it delivers the result report. Biopharmaceutical partners pay for pilot and research services as the work is completed.
10-K for FY2025, filed Mar 12, 2026
-
10-K for FY2025, filed Mar 12, 2026
FY2025 revenue by product or service ↗
$147.2M
-
10-K for FY2025, filed Mar 12, 2026
$147.2M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Screening revenue
Sold outright
10-K for FY2025, filed Mar 12, 2026 |
94%
FY2022: 72%
|
Screening revenue, FY2025
$138.6M Sources
|
Sold outright |
|
Development Services
Sold outright
|
5.8%
FY2022: 28%
|
Development Services, FY2025
$8.6M Sources
|
Sold outright |
Who Are Their Customers?
Patients obtain screening tests through healthcare systems, employers, digital health platforms, payors, concierge practices and life insurance providers, or directly through telemedicine. Biopharmaceutical companies engage GRAIL for pilot, research and development services.
10-K for FY2025, filed Mar 12, 2026The Company recognizes screening revenue from the sale of cancer screening testing services for patients. Patients obtain tests via…View ↗
Development services revenue includes development activities performed in partnership with biopharmaceutical companies. The Company’s…View ↗
Biopharmaceutical partners engage the Company to run pilot and research studies by sending patient samples and comparing the Company’s test…View ↗
Do Revenues Turn Into Profits?
No. It lost $408.4M in FY2025.
10-K for FY2025, filed Mar 12, 2026
−$562.2MView ↗
10-K for FY2025, filed Mar 12, 2026
−$408.4MView ↗
10-K for FY2025, filed Mar 12, 2026
−$299.9MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$110.2MView ↗
- ▼ −3% (Loss)
- vs −$114M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 6, 2026
Open tableView ↗
-
Jun 1, 2026
Josh Ofman is appointed chief executive officer
Sources
8-K, filed Jun 1, 2026
In connection with Dr. Joshua Ofman’s appointment as the Chief Executive Officer of GRAIL, Inc. (the “Company”), on June 1, 2026, the…View ↗
Loading...
